Indapamide

證據等級: L5

預測適應症: 0 個

Indapamide: Drug Repurposing Evaluation — Prediction Data Unavailable

One-Sentence Summary

Indapamide (DB00808) is a thiazide-like sulfonamide diuretic widely used internationally for hypertension and oedema associated with heart failure. No TxGNN repurposing predictions are available in this Evidence Pack, as the predicted indications list is empty — this evaluation cannot proceed to a standard repurposing assessment. The data collection pipeline retrieved only DrugBank records; South African regulatory, mechanism of action, and safety data were not successfully captured, leaving critical gaps across all evaluation domains.

Quick Overview

Item	Content
Original Indication	Hypertension; oedema (general pharmacological knowledge — not confirmed in Evidence Pack)
Predicted New Indication	Not available — TxGNN returned no candidates
TxGNN Prediction Score	Not available
Evidence Level	N/A
South Africa Market Status	Not marketed (per Evidence Pack data — see note below)
Number of SAHPRA Registrations	0 (per Evidence Pack data — see note below)
Recommended Decision	Hold

⚠️ Data Reliability Note: The Evidence Pack was built from DrugBank data only (inputs_received: ["drugbank"]). SAHPRA registration data was not collected. Indapamide is a well-established antihypertensive on the WHO Essential Medicines List and is expected to hold SAHPRA registration — the 0-registration result very likely reflects a collection gap rather than true absence from the South African market. Independent SAHPRA database verification is required before any regulatory conclusions are drawn.

Why This Assessment Cannot Be Completed

Two blocking data gaps prevent a standard repurposing evaluation:

1. No TxGNN repurposing predictions were generated. The predicted_indications array in the Evidence Pack is empty. TxGNN predictions require successful mapping of the drug to the knowledge graph via DrugBank ID and disease vocabulary. Without at least one predicted indication, there is no repurposing candidate to evaluate, no evidence to assess, and no mechanism-to-indication argument to construct.

2. Mechanism of action data is absent. The original_moa field is flagged as a data gap. For a repurposing evaluation, the mechanism of action is the analytical foundation: it explains why a drug approved for one condition might work in another. Without this, even if a prediction were available, the mechanistic rationale section could not be completed with confidence.

Until these two gaps are resolved, this report serves only as a data readiness assessment, not a full repurposing evaluation.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA at www.sahpra.org.za.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate cannot be evaluated for drug repurposing potential because no TxGNN predictions were generated and all drug-level data fields (MOA, safety warnings, contraindications) are unpopulated. There is no evidence base to assess, no mechanistic argument to make, and no regulatory foundation to work from.

To proceed, the following is needed:

[Blocking — DG001] Obtain the SAHPRA-approved Professional Information (PI) for Indapamide; extract approved indications, warnings, and contraindications from the PDF document
[High — DG002] Query the DrugBank API for Indapamide’s mechanism of action (DB00808) and populate original_moa
[Blocking] Re-run the TxGNN prediction pipeline with Indapamide’s DrugBank ID to generate predicted_indications; confirm that the drug node exists in the knowledge graph (data/node.csv) and that disease vocabulary mapping is functioning
[High] Independently verify SAHPRA registration status through the SAHPRA online register (https://www.sahpra.org.za/find-a-medicine/) to resolve the 0-registration anomaly
[Medium] Check whether Indapamide appears on the South African Essential Medicines List (EML) and the Standard Treatment Guidelines (STG), as this would be directly relevant to any repurposing access pathway
[Medium] Collect DDI data from DrugBank or a South African formulary source once the PI is available

Once the above data is retrieved and TxGNN predictions are generated, a full repurposing evaluation report should be regenerated using Evidence Pack v5 format.

This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. All adverse drug reactions should be reported to SAHPRA.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.